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A B s T r A C T
Background: The introduction of sirolimus has provided 
the opportunity to develop an immunosuppressive regimen 
without the nephrotoxic calcineurin inhibitors.
Methods: we conducted a first trial in 30 renal allograft 
recipients. Ten patients were followed prospectively and 
received sirolimus, to achieve a target blood level of 10 to 
15 ng/ml, induction therapy with one dose of daclizumab, 
low-dose steroids and mycophenolate mofetil. we compared 
this group with a historical control group of 20 patients who 
received our standard treatment consisting of tacrolimus, 
low-dose steroids, and mycophenolate mofetil.
results: After a mean follow-up of 15 weeks, seven patients 
developed an acute rejection in the sirolimus group (70%) 
compared with three patients in the tacrolimus group (15%) 
(p<0.01). 
Because of this unacceptable high rate of acute rejections 
we conducted a second prospective pilot study in nine 
patients. These patients received sirolimus in combination 
with two doses of daclizumab, high-dose steroids and 
mycophenolate mofetil. No rejections occurred under this 
immunosuppressive regimen; however, many immunosup-
pression-related adverse events were seen.
Conclusion: The present study demonstrates an 
unacceptably high rate of acute rejections (70%) in patients 
treated with sirolimus, daclizumab, mycophenolate mofetil 
and low-dose prednisolone. No rejections but many adverse 
events were seen when sirolimus was given in combination 
with high-dose steroids.
K E Y w o r d s
Calcineurin inhibitor, kidney transplantation, rejection, 
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i N T r o d u C T i o N
Immunosuppressive regimens including calcineurin 
inhibitors have greatly improved the results of kidney 
transplantations. Tacrolimus in combination with 
mycophenolate mofetil (MMF) and prednisolone decreased 
the number of acute rejection episodes within the first 
three months after transplantation to 15 to 20%. The 
incidence of graft failure from intractable acute rejections 
within one year after transplantation has dropped under 
the current regimen to below 5%. Therefore, tacrolimus 
combined with MMF and prednisolone is the standard 
regime in the first four months after transplantation in our 
centres. However, calcineurin inhibitors are nephrotoxic, 
which may eventually lead to loss of graft function. Long-
term results are therefore disappointing. The introduction 
of sirolimus has provided the opportunity to develop 
an immunosuppressive regimen without nephrotoxic 
calcineurin inhibitors.1
Obviously, removing calcineurin inhibitors from the 
immunosuppressive regime should not lead to a higher 
percentage of rejections. On the other hand, the additional 
amount of immunosuppression needed beside sirolimus to 
prevent acute rejection should not lead to an unacceptable 
amount of immunosuppression-related adverse events. 
Recently, Flechner et al.2 demonstrated in kidney transplant 
recipients that treatment with sirolimus, prednisolone, 
MMF, and additional IL-2 receptor blocker (basiliximab) 
was accompanied with an acute rejection percentage 
of 6.4%. However, the additional immunosuppression 
given, high-doses of steroids and two induction therapies, 
is much more than we are used to giving in combination 
with tacrolimus.
The main purpose of our study was to investigate whether 
the nephrotoxicity that occurs under the current standard 
immunosuppressive regimen with tacrolimus, low-dose 
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steroids and MMF can be decreased by a regimen with 
sirolimus, daclizumab, low-dose steroids and MMF without 
an increased incidence of acute rejections.
M A T E r i A l s  A N d  M E T h o d s
patients
We included primary and secondary adult (aged above 
18 years) renal allograft recipients in Nijmegen and 
Utrecht. Exclusion criteria consisted of HLA-identical 
living donor kidney; haemolytic uraemic syndrome as 
original renal disease; pregnancy or lactation; total white 
blood cell count <3*109/l or platelet count <100*109/l 
or haemoglobin level <5 mmol/l; current panel reactive 
antibodies (PRA) (last screening sample) >85%; the 
use of non-registered medication during the last four 
weeks preceding transplantation and during the study, 
a renal allograft transplant as part of a multiorgan 
transplantation; or treatment with CYP3A4 inhibitors or 
inductors. All recipients had a negative visual complement 
dependent cytotoxicity crossmatch. Flow cytometry T-cell 
crossmatching did not take place.
The patients who gave their informed consent were 
prospectively followed and treated with a calcineurin 
inhibitor free immunosuppressive protocol including 
sirolimus, daclizumab, MMF and low-dose steroids. This 
group was compared with a historical control group 
consisting of patients who met the same inclusion and 
exclusion criteria and had been treated directly before the 
start of the study with our standard immunosuppressive 
regimen including the calcineurin inhibitor tacrolimus, 
MMF and low-dose steroids. 
The study was approved by both ethical committees of the 
participating centres and performed in accordance with the 
standards of the Declaration of Helsinki.
immunosuppressive protocol and methods
First study
The patients in the calcineurin inhibitor free intervention 
group were treated with sirolimus at a loading dose of 
15 mg prior to transplant surgery. As soon as a patient was 
capable of taking oral medication a second loading dose 
of 12 mg was given, followed by a daily dose of 6 mg, to 
achieve a target blood level of 10 to 15 ng/ml. The target 
trough level remained steady throughout the study.
The patients in the sirolimus treatment arm also received 
daclizumab during the transplant surgery intravenously 
at a dose of 1 mg/kg. At weekly intervals during the first 
ten weeks following transplantation, the coverage of IL-2 
receptors was measured by flow cytometry.3 If free IL-2 
receptors were detected on the lymphocytes (reappearance 
of CD3posCD25pos lymphocytes) in the first four weeks, an 
extra dose of daclizumab at 1 mg/kg was given. 
The steroid regimen in the sirolimus treatment arm 
consisted of 100 mg prednisolone intravenously on day 0 
(day of transplantation); on day 1 to 5 prednisolone 4 times 25 
mg orally/iv. From day 6 till week 17 the steroids were slowly 
reduced from the starting dose (determined by weight: >70 
kg: 25 mg; 50 to 70 kg: 20 mg; <50 kg: 15 mg) to zero.
Patients in the historical control group were treated with 
tacrolimus at a dose of 0.2 mg/kg/day orally, divided over 
the morning and evening doses, to be started on day 1 or 
2 after transplantation. The target blood level in the first 
14 days was between 15 and 20 ng/ml, from week 3 to 7 
between 10 and 15 ng/ml and starting from week 7 the 
trough level should be 6 to 10 ng/ml.
The steroid regimen in the tacrolimus treatment group 
consisted of 100 mg prednisolone intravenously on day 0 
(day of transplantation); on day 1 and 2 prednisolone 25 mg 
four times orally/iv. From day 3 till week 17 the steroids 
were slowly reduced from the starting dose (determined by 
weight: >70 kg: 25 mg; 50 to 70 kg: 20 mg; <50 kg: 15 mg) 
to 0.1 mg/kg.
All patients were given MMF 750 mg twice daily from day 
1 or 2 onwards. For patients with a body weight of ≥90 kg, 
the dose was 1000 mg twice daily. In case of leucopenia or 
abdominal complaints, the dose was lowered (the minimal 
dose is 250 mg twice daily). 
All patients in whom a rejection was suspected underwent 
renal transplant biopsy, which were scored according the 
BANFF97 criteria.4 The primary study endpoints were 
the difference in renal function and the number of acute 
rejections between both treatment groups. 
Second study
Because of the unacceptably high rate of acute rejections 
in the above-described patients treated with sirolimus (see 
results) we conducted a second prospective pilot study in 
nine patients. They received sirolimus and MMF following 
the same protocol as described above. Besides the 
daclizumab given during the transplant surgery, they 
received an additional dose of daclizumab 1 mg/kg ten 
days after transplantation. The steroid regimen consisted 
of 500 mg methylprednisolone intravenously on day 0 (day 
of trans-plantation) to 2, and then oral prednisolone from 
120 mg to 30 mg by day 8, 27.5 mg by day 21, 25 mg by day 
30, tapered by 2.5 mg each month to a maintenance of 
7.5 mg daily.
results
First study
Ten patients included in the sirolimus group were compared 
with 20 patients who were treated with tacrolimus. Patient 
characteristics are summarised in table 1. Apart from 
more older donors and an unfavourable donor type profile 
in the sirolimus group, no significant differences were 
found. After a mean follow-up of 15 weeks, seven patients 
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in the sirolimus group had developed an acute rejection 
(70%; 95% confidence interval 42 to 98%). This was 
significantly more than the 15% rejection rate in the control 
group (p<0.01; Fisher’s exact test). Characteristics of the 
rejection episodes that occurred in the sirolimus group are 
mentioned in table 2. In four patients the renal allograft 
function recovered after three pulses of solumedrol alone. 
Two patients required a second course of solumedrol and 
one patient required antithymocyte globulin (ATG) after 
the solumedrol treatment before renal function improved. 
All patients were converted to tacrolimus and returned to 
a stable allograft function, with a mean serum creatinine 
of 159 mmol/l at one year after transplantation.
Four rejection episodes occurred within two weeks after 
transplantation. One of them was not biopsy proven 
because of the absence of renal tissue in the biopsy. 
In one of these patients there appeared to be no IL-2 
receptor blockade because the patient did not receive any 
daclizumab by mistake. In all the patients who received 
daclizumab, the IL-2 receptor was fully blocked at two 
and three months after transplantation after one dose of 
daclizumab.
Three rejections occurred between 8 and 15 weeks after 
transplantation. In all these cases the trough sirolimus 
level appeared to be below the target range at the time of 
rejection. The mean sirolimus trough levels were within 
the target range in the different time periods (table 3), but 
21% of the measurements were below target. This was 
comparable with 19% of the measurements below target 
in the tacrolimus treatment group.
Table 1. Demographics of the first study
sirolimus (n=10) Tacrolimus (n=20) p
recipients
Gender (M:F)
Age (years) (mean ± sd)
Age >65 years
7:3
54 ± 14
3
10:10
46 ± 13
1
NS
NS
NS
donors
Gender (M:F)
Age (years) mean ± sd)
Age >65 years
2:8
52 ± 15
3
8:12
47 ± 12
0
NS
NS
0.03
secondary transplant 1 1 NS
prA =0%
>0 and <50%
10
0
18
2
NS
hlA mismatches (mean ± sd 2.8 ± 0.9 2.5 ± 1.5 NS
donor type
Low risk (HB+LR)
High-risk (NHB+LUR)
3
7
14
6
NS
P<0.05
M = male; f = female; prA = panel reactive antibodies; hlA = human leucocyte antigen; NhB = non-heart beating; hB = heart beating; 
lr = living related; lur = living unrelated; Ns = not significant.
Table 2. Sirolimus-treated patients with acute rejections in the first study (n=7)
rejections 1 2 3 4 5 6 7
Week after KTx 2 1 14 15 8 2 1
Donor type NHB HB LUR LUR LUR LR LR
HLA mismatches (A-B-Dr) 1-0-0 0-2-1 1-1-1 1-1-2 0-1-2 1-1-1 1-1-1
Sirolimus level at rejection 
(ng/ml)
12 11 7.3 6.8 7.3 23 12
IL-2R blockade at 3 months No Yes Yes Yes Yes Yes Yes
Doses MMF at rejection 
(g/day)
1500 1500 1500 1500 1500 1500 2000
Steroid dose at rejection 
(mg/day)
20 25 2.5 2.5 7.5 22.5 25
Banff score:
First biopsy
Second biopsy
IIa + ATN
IIa
Ib Ib
Ia
IIa Ib No renal 
tissue
IIa
Therapy 3g Sol (twice) 3g Sol 3g Sol (twice) 3g Sol 3g Sol 3g Sol 
ATG
3g Sol
Creatinine one year after 
transplantation
230 168 130 160 147 126 150
KTx = kidney transplantation; NhB = non-heart beating; hB = heart beating; lur = living unrelated; lr = living related; hlA = human leucocyte 
antigen; il-2r blockade = interleukin 2 receptor blockade; MMf = mycophenolate mofetil; ATN = acute tubular necrosis; sol = solumedrol; 
ATg = antithymocyte globulin.
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One sirolimus-treated patient had a serious wound-healing 
problem.
Two of the three rejections in the tacrolimus group 
occurred within one week after transplantation. The 
third rejection occurred after 11 weeks. All of the patients 
required ATG after the course of solumedrol. One of them 
died as a consequence of this therapy.
Second study 
No acute rejections occurred in the second sirolimus 
treatment group (n=9) with high-dose additional 
immunosuppression after a mean follow-up of ten 
months. On the contrary, many serious adverse events 
were seen in this group, as summarised in table 4. Six 
patients (67%) suffered delayed wound healing, with a 
secondary wound infection in three of them. Operative 
abscess drainage was necessary in one of them. Four 
patients (44%) developed a lymphocele requiring drainage. 
In one patient a secondary infection developed in the 
lymphocele. One patient developed a pulmonary embolus 
and thereafter during anticoagulation therapy a bleeding in 
the transplant. After insertion of a vena cava filter, a vena 
cava inferior syndrome occurred and because of continuous 
bleeding in the kidney transplant a transplantectomy was 
performed and haemodialysis was restarted. Three patients 
(33%) developed proteinuria after transplantation. One 
of them is the above-described patient with pulmonary 
embolus. Another patient developed proteinuria of 12 g/day 
one week after transplantation. A kidney biopsy showed 
tubulointerstitial damage without glomerular damage. 
The proteinuria disappeared within one month after 
switching to tacrolimus. The third patient with proteinuria 
developed proteinuria till 1.5 g/day, which also disappeared 
after switching to cyclosporine. Three patients developed 
diarrhoea (33%), two of them requiring hospitalisation.
Three patients could be maintained on the sirolimus 
regimen during the mean follow-up period of 
ten months. The other six patients were switched to 
another immunosuppressive regimen because of 
severe complications. The time till the switch of 
immunosuppression and the main reason for switching 
is shown in figure 1. Two patients were switched to 
cyclosporine (after two and four months), three patients 
were switched to tacrolimus (one after one week and two 
after nine months), and one patient restarted haemodialysis 
after nephrectomy (seven weeks after transplantation).
Table 3. Sirolimus and tacrolimus trough levels in the first and second study
0-14 days 2-7 weeks 7 weeks-3 months
Tacrolimus trough level (ng/ml):
Target
Actually reached (mean ± SEM)
15-20
16.4 ± 0.9
10-15
12.3 ± 0.4
5-10
9.3 ± 0.3
Sirolimus trough level (ng/ml):
Target
Actually reached (mean ± SEM):
- First study
- Second study
10-15
13.4 ± 1.1
10.8 ± 0.8
10-15
14.9 ± 1.0
15.6 ± 0.9
10-15
11.8 ± 1.0
13.1 ± 0.9
sEM = standard error of the mean.
Table 4. Adverse events in sirolimus-treated patients (second study)
patient no. 1 2 3 4 5 6 7 8 9
Acute rejection - - - - - - - - -
Graft loss - + - - - - - - -
Surgical complications
- Delayed wound healing
- Haematoma
- Wound abscess/infection
- Lymphocele
+
+
+
-
+
-
+
-
+
-
-
+
-
-
-
-
+
-
+
+
+
-
-
+
+
-
-
+
-
-
-
-
-
-
-
-
Hypercholesterolaemia
(>6 mmol/l)
- - - - + + + + -
Hyperglycaemia
(fasting glucose >7 mmol/l)
+ + - - - + - - -
Pulmonary embolus - + - - - - - - -
Proteinuria (>1g/day) - + - + - + - - -
Candidiasis (oral) + - - - - - - - -
Diarrhoea - - + - + + - - -
Van den Akker, et al. Basic immunosuppression with sirolimus.
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d i s C u s s i o N
The use of calcineurin inhibitors has resulted in improved 
graft survival following kidney transplantation. However, 
this is associated with acute and chronic nephrotoxicity 
and may be an important contributor to the development 
of chronic transplant nephropathy and chronic graft 
loss.5 Calcineurin inhibitor nephrotoxicity is becoming 
increasingly prevalent, and is virtually universal by 
ten years after transplantation and progressive despite 
mild to moderate reductions in calcineurin doses.6 The 
introduction of sirolimus has provided the opportunity 
to develop an immunosuppressive regimen without 
nephrotoxic calcineurin inhibitors. Recently, Flechner et al.2 
demonstrated in kidney transplant recipients that treatment 
with sirolimus, prednisolone, MMF and additional IL-2 
receptor blocker (basiliximab) was accompanied with an 
acute rejection percentage of 6.4 vs 16.6% in the control 
arm (cyclosporine, prednisolone, MMF and IL-2 receptor 
blocker). At 12 months their sirolimus-treated patients 
enjoyed significantly better creatinine clearances than 
their cyclosporine-treated patients (81.1 and 61.1 ml/
min, respectively). However, the additional amount of 
immunosuppression given beside sirolimus is very high.
In our first study we achieved a rejection percentage of 70% 
in the sirolimus group compared with a 15% rejection rate 
in the tacrolimus group (p<0.01) within a mean follow-up 
of 15 weeks. Because of this unacceptably high rejection 
rate we ended the study prematurely and switched the 
patients to the standard immunosuppressive regimen 
including tacrolimus. To date, none of the patients have 
lost their grafts in the mean follow-up of 18 months. This 
high percentage of rejections cannot be explained by the 
fact that only patients with a high rejection risk were 
included in the sirolimus group. All rejections occurred 
in patients who underwent a first kidney transplantation 
with a PRA of 0% and there were no significant differences 
in the number of HLA mismatches and number of non-
heart beating donors between the groups. However, when 
we divided the donors into a low-risk group (heart beating 
and living related donors) and a high-risk group (non-heart 
beating and living unrelated donors) significantly more 
patients with an unfavourable donor type were found in 
the sirolimus-treated patients. Although this can be partly 
responsible for the bad outcome in the sirolimus group we 
do not think this can totally explain the very high rejection 
rate of 70%.
Four of the seven rejections in the sirolimus group 
occurred within two weeks after transplantation. One 
of these rejection episodes occurred in a patient who 
did not receive any daclizumab by mistake. In all other 
patients the IL-2 receptor was fully blocked at two and 
three months after transplantation by one infusion of 
daclizumab during transplant surgery. Three of the 
seven rejections occurred between 8 and 15 weeks after 
transplantation. These three rejections occurred when 
the prednisolone was reduced to below 10 mg/day, in 
accordance with the protocol. All patients used at least 
1500 mg MMF during the study period. At the time of 
rejection the sirolimus levels appeared to be lower than the 
target level in all three of them. The sirolimus levels were 
below target in 21% of all measured levels in the sirolimus 
group, but were never measured below 6.8 ng/ml. In the 
tacrolimus group 19% of all measured levels were below 
the target level. Some fluctuation in (sirolimus) trough 
levels is inevitable, but we must conclude that this seems 
immediately catastrophic in our low immunosuppressive 
regimen of the sirolimus group. There have been reports 
of calcineurin inhibitor free therapy, even without using 
antibody induction, that describe lower rates of acute 
rejection than we found. Kreis et al.7 using sirolimus, 
MMF and steroids reported an acute rejection rate of 
27.5% one year after transplantation and Groth et al.8 
using sirolimus, azathioprine and steroids reported an 
acute rejection rate of 41% at one year. In comparison with 
our protocol the target trough sirolimus level amounted 
to 30 ng/ml for the first two months in both studies and 
they started with 500 mg of methylprednisolone tapered 
to a maintenance dose of 10 mg daily. In the Symphony 
trial standard immunosuppression with normal dose 
cyclosporine (target trough level 150 to 300 ng/ml) was 
compared with three regimens with low doses of either 
cyclosporine, tacrolimus or sirolimus in combination with 
MMF, daclizumab and corticosteroids in 1645 de-novo 
renal transplant patients. The rate of biopsy-proven acute 
rejections with low-dose sirolimus (target trough level 4 
figure 1. Time frame (in months) for sirolimus-
treated patients: reason for switch of immunosup-
pression (second study)
1
0 1 2
CsA (wound abscess)
2
0 1
HD (transplant bleeding during anticoagulation for PE)
3
0 1 2 3 4 5 6 7 8 9 10
4
0
Tac (proteinuria 12g/day)
5
0 1 2 3 4 5 6 7 8 9 10 11
6
0 1 2 3 4
CsA (lymphocele, proteinuria and diarrhoea)
7
0 1 2 3 4 5 6 7 8 9
Tac (bronchus carcinoma)
8
0 1 2 3 4 5 6 7 8 9 10
9
0 1 2 3 4 5 6 7 8 9
Tac (oedema)
CsA = cyclosporine; HD = haemodialysis; PE = pulmonary embolus; Tac = tacrolimus.
Van den Akker, et al. Basic immunosuppression with sirolimus.
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to 8 ng/ml) at one year (35%) was higher than in the other 
groups (15 to 25%). The conclusion of this study was that 
the room for increasing sirolimus immunosuppression 
should be evaluated against the specific sirolimus toxicity 
profile.9,10 Contrary to our study, Flechner et al. started with 
500 mg methylprednisolone intravenously on day 0 to 2, 
and then oral prednisolone from 120 mg to 30 mg by day 
8, and thereafter slowly tapered to a maintenance dose of 
7.5 mg daily at eight months. Their mean trough sirolimus 
levels appeared to be 13.2 ± 7.9 ng/ml at one month after 
transplantation and 11.2 ± 5.8 ng/ml at three months after 
transplantation. They also gave a higher dose of MMF of 1 g 
twice daily instead of the 750 mg twice daily in our study 
and they used two gifts of basiliximab. These differences 
might explain the high rejection rate we found.
To prove this supposition we conducted a second 
prospective trial in nine patients. This protocol differed 
from the first by an additional dosage of daclizumab 
1 mg/kg at ten days after transplantation and higher doses 
of MMF and steroids according to the Flechner protocol. 
No acute rejections occurred under this treatment 
regimen. On the contrary many serious adverse events 
were seen, likely to be related to the combination of 
sirolimus and high-dose steroids. These findings are in 
accordance with Dean et al.9 using sirolimus, six gifts of 
antithymocyte globulin induction, MMF, and prednisone. 
They achieved an acute rejection rate of 9% at one year, 
but a wound complication rate of 35% in comparison 
with 10% in the tacrolimus control group. These adverse 
events and the interventions needed to treat them might 
also lead to a decline in renal function. This takes away 
the advantage of sirolimus, no nephrotoxicity, in the first 
place. However, the number of treated patients in our 
study is too small to compare renal function under the 
different regimens. In the Symphony trial where renal 
function was determined at 12 months they showed 
that low-dose tacrolimus was significantly superior to 
low-dose sirolimus with respect to glomerular filtration 
rate.11 The results from our study showed that in order 
to replace a calcineurin inhibitor by sirolimus aiming 
to avoid calcineurin nephrotoxicity, higher additional 
immunosuppression is needed to prevent an unacceptable 
rejection rate. Because of the immunosuppression-related 
adverse events we experienced under such a regimen we 
do not think there should be a place for a sirolimus-based 
regimen without calcineurin inhibitor in the direct post-
transplant period.
C o N C l u s i o N
The present study demonstrates an unacceptably high rate 
of acute rejections (70%) in patients treated with sirolimus, 
daclizumab, MMF and low-dose prednisolone in the first 
months after transplantation and no rejections but many 
adverse events when sirolimus was combined with two 
times induction therapy and high-dose prednisolone. 
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